This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
We agree with Dr Cullen's comment on the scientific importance of the fate of the dropout patients in our study. We had a dropout rate of 50% (15 patient), eight dropouts from the levamisole group and seven from the placebo group. Initially five patients decided not to take the experimental drug on completion of the initial studies; three from the placebo group, two from the levamisole group.The remaining ten patients were equally divided among the two groups. None of them had severe eczema. Of the five patients in the placebo group, two received medication for two months, went on vacation and cleared their eczema. Two received medication for the second two months, went on vacation and were unavailable for follow-up. One received medication for two months, but refused the immunologic measurements at the first two months control. He had mild eczema. Of the five patients in the
Alomar A, Giménez-Camarasa JM, de Moragas JM. The Dropout Patient-Reply. Arch Dermatol. 1979;115(5):639. doi:10.1001/archderm.1979.04010050063037
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: